Clinical Trial Update: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 trial of ME-401 in patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Indolent B-cell Non-hodgkin Lymphoma

Drugs mentioned

• ME-401

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma | Phase 1 | Status: COMPLETED